Evidence map›Paper›PMID 38268753›Full record

ArticleBMJ neurology open2024

Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease.

Neal S Parikh, Farah Wahbeh, Christopher Tapia, Mallory Ianelli, Vanessa Liao, Abhishek Jaywant, Hooman Kamel, Sonal Kumar, Costantino Iadecola

Open access · diamondAbstract read
In one paragraph

Article in BMJ neurology open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Neal S ParikhNeurology, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-8802-2380
Farah WahbehNeurology, Weill Cornell Medicine, New York, New York, USA.
Christopher TapiaNeurology, Weill Cornell Medicine, New York, New York, USA.
Mallory IanelliMedicine, Weill Cornell Medicine, New York, New York, USA.
Vanessa LiaoNeurology, Weill Cornell Medicine, New York, New York, USA.
Abhishek JaywantPsychiatry, Weill Cornell Medicine, New York, New York, USA.
Hooman KamelNeurology, Weill Cornell Medicine, New York, New York, USA.
Sonal KumarMedicine, Weill Cornell Medicine, New York, New York, USA.
Costantino IadecolaNeurology, Weill Cornell Medicine, New York, New York, USA.
Cornell University · US

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenicstroke (ARCADIA)U01NS095869 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRODERICK, JOSEPH PAUL, KAMEL, HOOMAN · 2017 to 2022
$22.0M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
MRI Detection of CarotId Plaques as a mecHanism for Embolic strokes of undeteRmined source (MRI DECIPHER)R01HL144541 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUPTA, AJAY, KAMEL, HOOMAN · 2019 to 2023
$3.9M
Quantitative Susceptibility Mapping for Stroke Risk Prediction of Vulnerable Carotid PlaquesR01NS123576 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ajay Gupta, Hooman Kamel · 2022 to 2026
$3.3M
Role of Liver Fibrosis in Cognitive Impairment and DementiaK23AG073524 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI PARIKH, NEAL S · 2021 to 2023
$585k
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NHLBI NIH HHS R01 HL144541NIA NIH HHS K23 AG073524NINDS NIH HHS R01 NS123576NINDS NIH HHS U01 NS095869NINDS NIH HHS U01 NS106513
6 · The paper itself

Abstract

Background: Data regarding the prevalence and phenotype of cognitive impairment in non-alcoholic fatty liver disease (NAFLD) are limited. Objective: We assessed the prevalence and nature of cognitive deficits in people with NAFLD and assessed whether liver fibrosis, an important determinant of outcomes in NAFLD, is associated with worse cognitive performance. Methods: We performed a prospective cross-sectional study. Patients with NAFLD underwent liver fibrosis assessment with transient elastography and the following assessments: Cognitive Change Index, Eight-Item Informant Interview to Differentiate Aging and Dementia Questionnaire (AD8), Montreal Cognitive Assessment (MoCA), EncephalApp minimal hepatic encephalopathy test and a limited National Institutes of Health Toolbox battery (Flanker Inhibitory Control and Attention Test, Pattern Comparison Test and Auditory Verbal Learning Test). We used multiple linear regression models to examine the association between liver fibrosis and cognitive measures while adjusting for relevant covariates. Results: We included 69 participants with mean age 50.4 years (SD 14.4); 62% were women. The median liver stiffness was 5.0 kilopascals (IQR 4.0-6.9), and 25% had liver fibrosis (≥7.0 kilopascals). Cognitive deficits were common in people with NAFLD; 41% had subjective cognitive impairment, 13% had an AD8 >2, 32% had MoCA <26 and 12% had encephalopathy detected on the EncephalApp test. In adjusted models, people with liver fibrosis had modestly worse performance only on the Flanker Inhibitory Control and Attention Task (β=-0.3; 95% CI -0.6 to -0.1). Conclusion: Cognitive deficits are common in people with NAFLD, among whom liver fibrosis was modestly associated with worse inhibitory control and attention.

Indexed as

ALZHEIMER'S DISEASEDEMENTIALIVER DISEASE

Identifiers

PMID38268753
PMCPMC10806883
OpenAlexW4391116770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.